These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30592133)

  • 1. Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis.
    Dane A; Spencer A; Rosenkranz G; Lipkovich I; Parke T;
    Pharm Stat; 2019 Mar; 18(2):126-139. PubMed ID: 30592133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke.
    Hemmings R; Koch A
    Pharm Stat; 2019 Mar; 18(2):140-144. PubMed ID: 30900391
    [No Abstract]   [Full Text] [Related]  

  • 3. Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
    Alosh M; Huque MF; Bretz F; D'Agostino RB
    Stat Med; 2017 Apr; 36(8):1334-1360. PubMed ID: 27891631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.
    Yusuf S; Wittes J; Probstfield J; Tyroler HA
    JAMA; 1991 Jul; 266(1):93-8. PubMed ID: 2046134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.
    Dmitrienko A; Muysers C; Fritsch A; Lipkovich I
    J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data-Driven Subgroup Identification in Confirmatory Clinical Trials.
    Bunouf P; Groc M; Dmitrienko A; Lipkovich I
    Ther Innov Regul Sci; 2022 Jan; 56(1):65-75. PubMed ID: 34327673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposed statistical framework for the management of subgroup analyses for large clinical trials.
    Luo X; Chen P; Wu AC; Pan G; Li M; Chen G; Dong Q; Cline GA; Dornseif BE; Jin Z
    Contemp Clin Trials; 2015 Nov; 45(Pt B):239-243. PubMed ID: 26388115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
    Zhang S; Liang F; Li W; Hu X
    J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design.
    Matsui S; Crowley J
    Clin Cancer Res; 2018 Mar; 24(5):994-1001. PubMed ID: 28887317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
    Hemmings R
    J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible Bayesian subgroup analysis in early and confirmatory trials.
    Bunn V; Liu R; Lin J; Lin J
    Contemp Clin Trials; 2020 Nov; 98():106149. PubMed ID: 32942055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The case for cross-over trials in phase III.
    Jones B; Lewis JA
    Stat Med; 1995 May 15-30; 14(9-10):1025-38. PubMed ID: 7569498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
    Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
    J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.
    Tanniou J; van der Tweel I; Teerenstra S; Roes KC
    BMC Med Res Methodol; 2016 Feb; 16():20. PubMed ID: 26891992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Federation of Statisticians in the Pharmaceutical Industry's position on access to clinical trial data.
    Fletcher C; Driessen S; Burger HU; Gerlinger C; Biesheuvel E;
    Pharm Stat; 2013; 12(6):333-6. PubMed ID: 24136872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):146-168. PubMed ID: 29172961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.